Global T-Cell Therapy Market - Distribution by Type of Therapy, Target Indications, Target Antigens, Key Players and Key Geographies : Industry Trends and Global Forecasts, 2022-2035

Cancer is known to be one of the leading causes of deaths worldwide. In fact, as per the WHO, close to 10 million cancer related deaths were reported in 2020. Further, it is estimated that, by the end of 2040, 27.5 million new cases will be added to the global cancer burden, exerting tremendous physical, emotional and financial strain on affected individuals, their families, communities and national health systems. Although there are several treatment options available to control disease progression and keep malignant cells from spreading throughout the body, lasting remission is difficult to achieve. In this context, immunotherapies, a relatively recent addition to the gamut of anticancer interventions, have demonstrated significant promise. Amidst the current initiatives undertaken to develop more targeted anti-cancer therapies, T-cell therapies (specifically CAR-T, TCR and TIL therapies) have emerged as a promising option, owing to their ability to eradicate tumor cells from the body with minimal treatment-related side effects. Overall, this highly specific and promising form of T-cell treatment, which harnesses the versatile effector machinery of the human immune system, has revolutionized cancer treatment, globally. Given the consistent increase in number of cell therapies being developed and launched, this upcoming therapeutic segment is on its way to becoming one of the highest valued markets within the biopharmaceutical industry. A number of chimeric antigen receptor T-cell (CAR-T) therapies have so far been evaluated and approved for several hematological malignancies, including KYMRIAH® (Novartis), YESCARTA® (Gilead Sciences), TECARTUS™ (Gilead Sciences), Breyanzi® (Bristol Myers Squibb), Abecma™ (Bristol Myers Squibb) and CARVYKTI™ (Janssen Biotech / Legend Biotech). It is worth mentioning that, recently, KIMMTRAK® (Immunocore) became the first T-cell receptor (TCR) therapy to receive approval from the USFDA.

Presently, more than 250 companies are engaged in the development of more than 1,200 early and late-stage T-cell therapies, worldwide. Several promising leads are anticipated to be commercially launched over the coming decade, following which the market is projected to grow at a substantial pace. Over 6,800 patents related to CAR-T, TCR and TIL therapeutics have been recently filed / granted, demonstrating the continued innovation in this domain. In addition, close to 440 collaborations have been inked between industry / academic stakeholders to advance the development of various pipeline candidates. Moreover, to fund product development initiatives in this domain, capital investments worth USD 30 billion have been made by various private and public sector investors in the last few years. Driven by the ongoing pace of innovation in this field, sufficient financial support from investors and encouraging clinical trial results, the T-cell immunotherapy market is anticipated to witness substantial growth in the mid to long-term.

SCOPE OF THE REPORT

The "Global T-Cell (CAR-T, TCR, and TIL) Therapy Market (6th Edition) - Distribution by Type of Therapy (CAR-T, TCR and TIL), Target Indications (Acute Lymphoblastic Leukemia, Non-Hodgkin's Lymphoma, Melanoma, Bladder Cancer, Lung Cancer, Head and Neck Cancer, Multiple Myeloma, Sarcoma, Chronic Lymphocytic Leukemia, Ovarian Cancer, Esophageal Cancer, Colorectal Cancer, Nasopharyngeal Carcinoma, Hepatocellular Carcinoma, Acute Myeloid Leukemia and Renal Cell Carcinoma), Target Antigens (CD19, BCMA, CD19/22, EGFR, NY-ESO-1, gp100, p53, EBV, MUC1, WT-1 and others), Key Players and Key Geographies (North America, Europe, Asia Pacific, Latin America, Middle East and North Africa, and Rest of the World) - Global Forecast 2022-2035" report features an extensive study of the current market landscape and the future potential of T-cell immunotherapies. The report highlights the efforts of several stakeholders engaged in this rapidly evolving segment of the biopharmaceutical industry. Amongst other elements, the report features the following:

A detailed assessment of the current market landscape of T-cell immunotherapies with respect to type of developer (industry and non-industry), phase of development (approved, phase III, phase II / III, phase II, phase I / II, phase I, clinical (phase unknown), preclinical), therapeutic area (oncological disorders, non-oncological disorders and undisclosed), key target indication (acute lymphoblastic leukemia, B-cell lymphoma, multiple myeloma, non-Hodgkin lymphoma, acute myeloid leukemia, hepatocellular carcinoma, diffuse large B-cell lymphoma, pancreatic cancer, gastric cancer, lung cancer, mantle cell lymphoma, ovarian cancer, breast cancer and follicular lymphoma), key target antigen (CD19, BCMA, CD22, CD20, Meso, CD7, HER2, GPC3, GD2, CD123, MUC, EGFR and CD38), source of T-cells (autologous and allogeneic), route of administration (intravenous, intratumoral, intraperitoneal, intrapleural, intracranial and others), dose frequency (single dose, multiple doses and split doses), patient segment (children, adults and seniors) and type of therapy (monotherapy and combination therapy). Additionally, it highlights the most active industry and non-industry players (in terms of number of pipeline candidates) engaged in the development of CAR-T cell therapies. Further, chapter also includes developer landscape analysis based on some relevant parameters, including year of establishment, company size (small, mid-sized and large) and location of headquarters (North America, Europe and Asia Pacific).

An analysis of key insights derived from the study featuring a competitive analysis, highlighting the popular target antigens related to hematological malignancies and solid tumors. Additionally, it includes CAR construct analysis of clinical-stage CAR-T therapies based on the generation of CAR (first generation, second generation, third generation and fourth generation), type of binding domain (murine, humanized, fully human and rabbit derived), type of virus used (lentivirus and retrovirus), type of gene transfer method used (transduction and transfection) and type of co-stimulatory domain used.

A detailed analysis of completed, ongoing and planned clinical studies related to CAR-Ts, TCRs and TIL, based on several relevant parameters, such as trial registration year, enrolled patient population, trial recruitment status, trial phase, target patient segment, type of sponsor / collaborator, most active players and regional distribution of trials.

An insightful analysis highlighting the key opinion leaders (KOLs) in this domain featuring an analysis of the various principal investigators of clinical trials related to CAR-Ts, TCRs and TILs, considering them to be KOLs, who are actively involved in R&D of T-cell therapies. In addition, the chapter presents an analysis, comparing the relative expertise of KOLs based on a proprietary scoring criterion and that of a third party.

Elaborate profiles of marketed and mid- to late stage clinical products (phase I/II or above); each profile features an overview of the therapy, its mechanism of action, dosage information, details on the cost and sales information (wherever available), clinical development plan, and key clinical trial results.

A detailed discussion on innovative technology platforms that are being used for the development of T-cell therapies, along with profiles of key technology providers, and a relative competitiveness analysis of different gene editing platforms (used for the development of T-cell therapies), based on various parameters, such as ease of system design, cost of technology, level of toxicity and efficiency of technology.

An analysis of various type of partnership that have been inked between several stakeholders in the domain of T-cell therapies, covering various type of partnership such as, R&D agreements, license agreements (specific to technology platforms and product candidates), product development and commercialization agreements, manufacturing agreements, clinical trial collaborations, product supply management agreements, joint ventures and others.

An analysis of the investments that have been made into companies that have proprietary T-cell based products / technologies, including seed financing, venture capital financing, capital raised from IPOs and subsequent offerings, grants and debt financing.

An in-depth analysis of patents related to CAR-Ts, TCRs and TILs, filed / granted till 2022, based on several relevant parameters, such as type of patent, publication year, geographical distribution, Cooperative Patent Classification (CPC) symbols, emerging focus areas, type of applicant, leading players (on the basis of number of patents) and patent benchmarking. In addition, it features a patent valuation analysis which evaluates the qualitative and quantitative aspects of the patents.

A case study on other T-cell based therapies, apart from CAR-Ts, TCRs and TILs, including a detailed analysis of approved / pipeline products, featuring information on current phase of development, target therapeutic area(s), type of T-cells used and source of T-cells.

A case study on manufacturing cell therapy products, highlighting the key challenges, and a detailed list of contract service providers and in-house manufacturers involved in this space.

An elaborate discussion on various factors that form the basis for the pricing of cell-based therapies. It features different models / approaches that a pharmaceutical company may choose to adopt to decide the price of a T-cell based immunotherapy that is likely to be marketed in the coming years.

A review of the key promotional strategies being adopted by the developers of the approved CAR-T cell therapies, namely Kymriah®, Yescarta®, Tecartus™, Breyanzi®, Abecma™, Carvykti™ and TCR-based therapies (Kimmtrak®).

Elaborate profiles of the several leading players in the domain of T-cell immunotherapies. Each company profile includes an overview of the developer and brief description of the product portfolio specific to CAR-T, TCR and TIL therapies, technology portfolio (if available), recent developments related to T-cell immunotherapies and manufacturing capabilities of the companies. Additionally, we have provided details of the strategic / venture capital investments made in these companies.

One of the key objectives of the report was to estimate the existing market size and identify potential growth opportunities for T-cell immunotherapies over the coming decade. Based on several relevant parameters, such as target consumer segments, region specific adoption rates and expected prices of such products, we have developed informed estimates of the likely evolution of the market over the period 2022-2035. The report also includes likely sales forecasts of T-cell immunotherapies that have been already commercialized or are in the late stages of development. Additionally, it features market size projections for the overall T-cell immunotherapies market, wherein both the current and upcoming opportunity is segmented across [A] type of therapy (CAR-T, TCR and TIL), [B] target indications (acute lymphoblastic leukemia, non-Hodgkin's lymphoma, melanoma, bladder cancer, lung cancer, head and neck cancer, multiple myeloma, sarcoma, chronic lymphocytic leukemia, ovarian cancer, esophageal cancer, colorectal cancer, nasopharyngeal carcinoma, hepatocellular carcinoma, acute myeloid leukemia, and renal cell carcinoma), [C] target antigens (CD19, BCMA, CD19/22, EGFR, NY-ESO-1, gp100, p53, EBV, MUC1, WT-1 and others), [D] key players and [E] key geographies (North America, Europe, Asia Pacific, Latin America, Latin America, Middle East and North Africa and rest of the world). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios namely the conservative, base and optimistic scenarios, which represent different tracks of the industry's evolution.

RESEARCH METHODOLOGY

The data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews / surveys with experts in this domain (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Wherever possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include:

Annual reports
Investor presentations
SEC filings
Industry databases
News releases from company websites
Government policy documents
Industry analysts' views

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

KEY QUESTIONS ANSWERED

What are the prevalent R&D trends related to T-cell immunotherapies (specifically CAR-Ts, TCRs and TILs)?

What kind of clinical conditions can be treated using T-cell immunotherapies?

Who are the leading industry and non-industry players in this market?

In which geographies extensive research on T-cell immunotherapy is being conducted?

What kind of partnership models are commonly adopted by industry stakeholders?

Who are the key investors in T-cell immunotherapy domain?

Who are the key opinion leaders / experts from renowned academic and research institutes who can help drive product development efforts in this domain?

How is the intellectual property landscape for global T-cell therapies likely to evolve in the foreseen future?

Who are the key service providers (CMOs / CDMOs) with capabilities to develop and manufacture T-cell therapies?

What are the key factors that are likely to influence the evolution of the T-cell immunotherapies market?

How is the current and future market opportunity likely to be distributed across key market segments?

What are the key promotional strategies used by companies having marketed products?

CHAPTER OUTLINES

Chapter 2 is an executive summary of the insights captured during our research. It offers a high-level view on the likely evolution of the T-cell immunotherapy market in the short to mid-term and long term.

Chapter 3 provides a general overview of T-cell immunotherapies. In this section, we have briefly discussed the conventional forms of therapy that are being used for the treatment of various oncological indications. Further, it includes a discussion on the advent and historical evolution of cancer immunotherapy, general manufacturing procedure of T-cell immunotherapies, factors supporting the growing popularity of T-cell based therapies and the challenges associated with such therapies. Moreover, it features detailed sections on the three major types of T-cell immunotherapies, namely CAR-T, TCR and TIL-based therapies, which are the main focus of the study.

Chapter 4 includes detailed assessment of the current market landscape of more than 970 CAR-T cell therapies that are currently approved or are in different stages of the development. It features a comprehensive analysis of pipeline molecules with respect to the type of developer (industry and non-industry), phase of development (approved, phase III, phase II / III, phase II, phase I / II, phase I, clinical (phase unknown), preclinical), therapeutic area (oncological disorders, non-oncological disorders and undisclosed), key target indication (acute lymphoblastic leukemia, B-cell lymphoma, multiple myeloma, non-Hodgkin lymphoma, acute myeloid leukemia, hepatocellular carcinoma, diffuse large B-cell lymphoma, pancreatic cancer, gastric cancer, lung cancer, mantle cell lymphoma, ovarian cancer, breast cancer and follicular lymphoma), key target antigen (CD19, BCMA, CD22, CD20, Meso, CD7, HER2, GPC3, GD2, CD123, MUC, EGFR and CD38), source of T-cells (autologous and allogeneic), route of administration (intravenous, intratumoral, intraperitoneal, intrapleural, intracranial and others), dose frequency (single dose, multiple doses and split doses), patient segment (children, adults and seniors) and type of therapy (monotherapy and combination therapy). Additionally, it highlights the most active industry and non-industry players (in terms of number of pipeline candidates) engaged in development of CAR-T cell therapies. Further, chapter also includes developer landscape analysis based on some relevant parameters, including year of establishment, company size (small, mid-sized and large) and location of headquarters (North America, Europe and Asia Pacific).

Chapter 5 includes detailed assessment of the current market landscape of more than 190 TCR-based therapies that are currently approved or are in different stages of development. It features a comprehensive analysis of pipeline molecules with respect to the type of developer (industry and non-industry), phase of development (approved, phase II, phase I / II, phase I, clinical (phase unknown), preclinical), therapeutic area (oncological disorders, non-oncological disorders and undisclosed), key target indication (lung cancer, melanoma, hepatocellular carcinoma, cervical cancer, ovarian cancer, sarcoma, breast cancer, gastric cancer, multiple myeloma, pancreatic cancer, acute myeloid leukemia, myelodysplastic syndrome and nasopharyngeal carcinoma), key target antigen (NY-ESO-1, MAGE, HBV, PRAME, KRAS, EBV, HPV, Neoantigen, LAGE-1a, Meso and HLA), source of T-cells (autologous and allogeneic), route of administration (intravenous and intratumoral), dose frequency (single dose, multiple doses and split doses), patient segment (children, adults and seniors), and type of therapy (monotherapy and combination therapy). Additionally, it highlights the most active industry and non-industry players (in terms of number of pipeline candidates) engaged in the development of TCR-based therapies. Further, chapter also includes developer landscape analysis based on some relevant parameters, including year of establishment, company size (small, mid-sized and large) and location of headquarters (North America, Europe and Asia Pacific).

Chapter 6 includes detailed assessment of current market landscape of more than 75 TIL-based therapies that are currently in different stages of development. Additionally, it features a comprehensive analysis of pipeline molecules with respect to the type of developer (industry and non-industry), phase of development (phase III, phase II, phase I / II, phase I, clinical (phase unknown), preclinical), therapeutic areas (oncological disorders, non-oncological disorders), key target indications (melanoma, ovarian cancer, cervical cancer, lung cancer, pancreatic cancer, sarcoma, breast cancer and squamous cell carcinoma ), source of T-cells (autologous and allogeneic), route of administration (intravenous and hepatic arterial infusion), dose frequency (single dose and multiple doses), patient segment (children, adults, and seniors), and type of therapy (monotherapy and combination therapy). Further, it highlights the most active industry and non-industry players (in terms of number of pipeline candidates) engaged in the development of TIL-based therapies. The chapter also features an analyses on the developers landscape based on some relevant parameters, including year of establishment, company size (in terms of number of employees), and location of headquarters ( North America, Europe and Asia-Pacific).

Chapter 7 presents a collection of key insights derived from the study. It includes a bubble analysis, highlighting the most popular target antigens related to hematological malignancies and solid tumors. Additionally, it includes CAR construct analysis of clinical-stage CAR-T therapies based on the generation of CAR (first generation, second generation, third generation and fourth generation), type of binding domain (murine, humanized, fully human and rabbit derived), type of virus used (lentivirus and retrovirus), type of gene transfer method used (transduction and transfection) and type of co-stimulatory domain used.

Chapter 8 presents a detailed analysis of completed, ongoing and planned clinical studies related to CAR-Ts, TCRs and TILs, based on several relevant parameters, such as trial registration year, enrolled patient population, trial recruitment status, trial phase, target patient segment, type of sponsor / collaborator, most active players and regional distribution of trials.

Chapter 9 presents an analysis highlighting the key opinion leaders (KOLs) in this domain, featuring an analysis of the various principal investigators of clinical trials related to CAR-Ts, TCRs and TILs, considering them to be KOLs, who are actively involved in R&D of T-cell therapies. In addition, the chapter presents an analysis, comparing the relative expertise of KOLs based on a proprietary scoring criterion and that of a third party.

Chapter 10 provides detailed profiles of marketed and mid to late stage CAR-T therapies (phase I/II or above). Each profile features an overview of the therapy, its mechanism of action, dosage information, details on the cost and sales information (wherever available), clinical development plan, and key clinical trial results.

Chapter 11 provides detailed profiles of the mid to late stage TCR therapies. Each profile features an overview of the therapy, its mechanism of action, dosage information, details on the cost and sales information (wherever available), clinical development plan, and key clinical trial results.

Chapter 12 provides detailed profiles of the mid to late stage TIL therapies. Each profile features an overview of the therapy, its mechanism of action, dosage information, details on the cost and sales information (wherever available), clinical development plan, and key clinical trial results.

Chapter 13 provides a list of technology platforms that are either available in the market or under designed for the development of T-cell immunotherapies. A detailed discussion on innovative technology platforms that are being used for the development of T-cell therapies, along with profiles of key technology providers, and a relative competitiveness analysis of different gene editing platforms (used for the development of T-cell therapies), based on various parameters, such as ease of system design, cost of technology, level of toxicity and efficiency of technology.

Chapter 14 features an analysis of the various collaborations and partnerships that have been inked amongst players in this market, in the past few years. Further, the partnership activity in this domain has been analyzed on the basis of the type of partnership model (R&D collaborations, license agreements (specific to technology platforms and product candidates), product development and commercialization agreements, manufacturing agreements, clinical trial collaborations, product supply management agreements and others), companies involved, type of therapy, prominent product candidates involved and regional distribution of the collaborations.

Chapter 15 provides details on the various investments and grants that have been awarded to several stakeholders focused on the development of T-cell immunotherapies. It includes a detailed analysis of the funding instances that have taken place in the period between 2000 to 2020, highlighting the growing interest of venture capital (VC) community and other strategic investors in this domain.

Chapter 16 provides an in-depth analysis of patents related to CAR-Ts, TCRs and TILs, filed / granted till 2022, based on several relevant parameters, such as type of patent, publication year, geographical distribution, Cooperative Patent Classification (CPC) symbols, emerging focus areas, type of applicant, leading players (on the basis of number of patents) and patent benchmarking. In addition, it features a patent valuation analysis which evaluates the qualitative and quantitative aspects of the patents.

Chapter 17 features details of other novel T-cell based therapies, apart from CAR-Ts, TCRs and TILs, which are currently being investigated. It presents a detailed analysis of the approved / clinical products in this domain, including information on current phase of development, target therapeutic areas, type of cells, and source of T-cells. Additionally, we have provided a brief overview of the upcoming therapies, along with details on their mechanisms of action.

Chapter 18 provides insights on cell therapy manufacturing, highlighting the current challenges that exist in this domain, and the pre-requisites for owning and maintaining cell therapy manufacturing sites. Additionally, it includes a detailed list of various cell therapy manufacturers, covering both contract manufacturing organizations and companies with in-house manufacturing capabilities. For the players mentioned in the chapter, we have included details on location of various manufacturing facilities, the products being manufactured, scale of operation and compliance to cGMP standards.

Chapter 19 highlights our views on the various factors that must be taken into consideration while deciding the prices of cell-based therapies. It features discussions on different models / approaches that a pharmaceutical company may choose to follow to decide the price at which their T-cell based immunotherapy product can be marketed. Additionally, we have provided a brief overview of the reimbursement consideration for T-cell immunotherapies and a case study on the National Institute for Health and Care Excellence (NICE) appraisal of CAR-T therapy.

Chapter 20 features an elaborate discussion on the future commercial opportunity offered by T-cell therapies. It provides a comprehensive market forecast analysis for T-cell products that are approved or are in phase I/II, phase II and phase III of development, taking into consideration the target patient population, existing / future competition, likely adoption rates and the likely price of different therapies. The chapter also presents a detailed market segmentation on the basis of [A] type of therapy (CAR-T, TCR and TIL), [B] target indications (acute lymphoblastic leukemia, non-Hodgkin's lymphoma, melanoma, bladder cancer, lung cancer, head and neck cancer, multiple myeloma, sarcoma, chronic lymphocytic leukemia, ovarian cancer, esophageal cancer, colorectal cancer, nasopharyngeal carcinoma, hepatocellular carcinoma, acute myeloid leukemia, and renal cell carcinoma), [C] target antigens (CD19, BCMA, CD19/22, EGFR, NY-ESO-1, gp100, p53, EBV, MUC1, WT-1 and others), [D] key players and [E] key geographies (North America (US and Canada), Europe (UK, Germany, France, Italy, Spain and rest of EU), Asia Pacific (China, Japan, Australia), Latin America, Latin America, Middle East and North Africa and rest of the world).

Chapter 21 highlights the key promotional strategies that are being implemented by the developers of the approved CAR-T Cell therapies (Kymriah®, Yescarta®, Tecartus™, Breyanzi®, Abecma™, Carvykti™) and TCR-based therapies (Kimmtrak®). The promotional aspects covered in the chapter include details that are provided on the product website (covering key messages for patients and healthcare professionals), patient support offerings and informative downloadable content.

Chapter 22 includes brief company profiles of the leading players in the domain of T-cell immunotherapies. Each company profile includes an overview of the developer and brief description of the product portfolio specific to CAR-T, TCR and TIL therapies, technology portfolio (if available), recent developments related to T-cell immunotherapies and manufacturing capabilities of the companies. Additionally, we have provided details of the strategic / venture capital investments made in these companies.

Chapter 23 is a summary of the overall report. In this chapter, we have provided a list of key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters.

Chapter 24 is a collection of transcripts of interviews conducted with key stakeholders in the market. In this chapter, we have presented the details of our conversations with Tim Oldham (Former Chief Executive Officer, Cell Therapies), Troels Jordansen (Chief Executive Officer, Glycostem Therapeutics, Wei (William) Cao (Chief Executive Officer, Gracell Biotechnologies), Victor Lietao Li (Co-Founder and Chief Executive Officer, Lion TCR), Miguel Forte (Chief Operating Officer, TxCell), Adrian Bot (Vice President, Scientific Affairs, Kite Pharma), Vincent Brichard (Vice President, Immuno-Oncology, Celyad), Peter Ho (Former Director, Process Development, Iovance Biotherapeutics), Brian Dattilo (Manager of Business Development, Waisman Biomanufacturing), Aino Kalervo (Former Competitive Intelligence Manager, Strategy & Business Development, Theravectys), Xian-Bao Zhan (Professor of Medicine and Director, Department of Oncology, Changhai Hospital) and Enkhtsetseg Purev (Assistant Professor of Medicine, University of Colorado).

Chapter 25 is an appendix, which provides tabulated data and numbers for all the figures included in the report.

Chapter 26 is an appendix, which contains the list of companies and organizations mentioned in the report.

Product Code: RA100369

1. PREFACE

1.1. Scope of the Report
1.2. Market Segmentations
1.3. Research Methodology
1.4. Key Questions Answered
1.5. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

3.1. Chapter Overview
3.2. Pillars of Cancer Therapy
3.3. Overview of Immunotherapies
3.4. Fundamentals of Cancer Immunotherapy
3.5. Classification of Cancer Immunotherapies
- 3.5.1. By Mechanism of Action
- 3.5.2. By Type of Target
- 3.5.3. By Approach
- 3.5.4. By Product Class
3.6. T-Cell Immunotherapies
- 3.6.1. Historical Evolution
- 3.6.2. Key Considerations for Developing T-Cell Immunotherapies
- 3.6.3. Strategies Employed for the Redirection of T-Cells
- 3.6.4. Manufacturing of Engineered T-Cells
- 3.6.5. T-Cell Transduction and Transfection Methods
3.7. Chimeric Antigen Receptor T-Cell (CAR-T) Therapy
- 3.7.1. Development History
- 3.7.2. Anatomical Layout of CAR
- 3.7.3. Development of CAR-T Cells
- 3.7.4. Universal CAR-T Cells
- 3.7.5. Route of Administration
- 3.7.6. Case Study on CD19 CAR-T Cell Therapies
- 3.7.7. Challenges Associated with Use of CAR-T Cell Therapies
3.8. T-Cell Receptor (TCR)-based Cell Therapy
- 3.8.1. Development History
- 3.8.2. Anatomical Layout of TCR
- 3.8.3. Development of TCR Therapy
- 3.8.4. Comparison of CAR-T and TCR-based Therapies
3.9. Tumor Infiltrating Lymphocyte (TIL)-based Cell Therapy
- 3.9.1. Development History
- 3.9.2. Development of TILs Therapy
3.10. Key Benefits and Roadblocks
3.11. Concluding Remarks

4. CAR-T CELL THERAPIES: MARKET LANDSCAPE

4.1. Chapter Overview
4.2. CAR-T Cell Therapies: Overall Market Landscape
- 4.2.1. Analysis by Type of Developer
- 4.2.2. Analysis by Phase of Development
- 4.2.3. Analysis by Therapeutic Area
- 4.2.4. Analysis by Phase of Development and Therapeutic Area
- 4.2.5. Analysis by Key Target Indications
- 4.2.6. Analysis by Key Target Antigens
- 4.2.7. Analysis by Source of T-Cells
- 4.2.8. Analysis by Phase of Development and Source of T-Cells
- 4.2.9. Analysis by Route of Administration
- 4.2.10. Analysis by Dosing Frequency
- 4.2.11. Analysis by Target Patient Segment
- 4.2.12. Analysis by Type of Therapy
- 4.2.13. Most Active Industry Players: Analysis by Number of CAR-T Cell Therapies
- 4.2.14. Most Active Non-Industry Players: Analysis by Number of CAR-T Cell Therapies
4.3. CAR-T Cell Therapies: Overall Developer Landscape
- 4.3.1. Analysis by Year of Establishment
- 4.3.2. Analysis by Company Size
- 4.3.3. Analysis by Location of Headquarters

5. TCR-BASED THERAPIES: MARKET LANDSCAPE

5.1. Chapter Overview
5.2. TCR-based Therapies: Overall Market Landscape
- 5.2.1. Analysis by Type of Developer
- 5.2.2. Analysis by Phase of Development
- 5.2.3. Analysis by Therapeutic Area
- 5.2.4. Analysis by Phase of Development and Therapeutic Area
- 5.2.5. Analysis by Key Target Indication
- 5.2.6. Analysis by Key Target Antigen
- 5.2.7. Analysis by Source of T-Cells
- 5.2.8. Analysis by Route of Administration
- 5.2.9. Analysis by Phase of Development and Route of Administration
- 5.2.10. Analysis by Dosing Frequency
- 5.2.11. Analysis by Target Patient Segment
- 5.2.12. Analysis by Type of Therapy
- 5.2.13. Analysis by Phase of Development and Type of Therapy
- 5.2.14. Most Active Industry Players: Analysis by Number of TCR-based Therapies
- 5.2.15. Most Active Non-Industry Players: Analysis by Number of TCR-based Therapies
5.3. TCR-based Therapies: Overall Developer Landscape
- 5.3.1. Analysis by Year of Establishment
- 5.3.2. Analysis by Company Size
- 5.3.3. Analysis by Location of Headquarters

6. TIL-BASED THERAPIES: MARKET LANDSCAPE

6.1. Chapter Overview
6.2. TIL-based Therapies: Overall Market Landscape
- 6.2.1. Analysis by Type of Developer
- 6.2.2. Analysis by Phase of Development
- 6.2.3. Analysis by Therapeutic Area
- 6.2.4. Analysis by Key Target Indication
- 6.2.5. Analysis by Source of T-Cells
- 6.2.6. Analysis by Route of Administration
- 6.2.7. Analysis by Dosing Frequency
- 6.2.8. Analysis by Target Patient Segment
- 6.2.9. Analysis by Type of Therapy
- 6.2.10. Most Active Industry Players: Analysis by Number of TIL-based Therapies
- 6.2.11. Most Active Non-Industry Players: Analysis by Number of TIL-based Therapies
6.3. TIL-based Therapies: Overall Developer Landscape
- 6.3.1. Analysis by Year of Establishment
- 6.3.2. Analysis by Company Size
- 6.3.3. Analysis by Location of Headquarters

7. KEY INSIGHTS

7.1. Chapter Overview
7.2. T-Cell Immunotherapies: Competitive Analysis by Popular Target Antigen
- 7.2.1. Popular Targets Related to Hematological Malignancies
- 7.2.2. Popular Targets Related to Solid Tumors
7.3. T-Cell Immunotherapies: CAR Construct Analysis
- 7.3.1. Analysis by Generation of CAR
- 7.3.2. Analysis by Type of scFv Antibody
- 7.3.3. Analysis by Type of Virus Used
- 7.3.4. Analysis by Type of Gene Transfer Method Used
- 7.3.5. Analysis by Co-Stimulatory Domain

8. CLINICAL TRIAL ANALYSIS

8.1. Chapter Overview
8.2. Scope and Methodology
8.3. CAR-T Cell Therapies: Clinical Trial Analysis
- 8.3.1. Analysis by Trial Registration Year
- 8.3.2. Analysis by Trial Registration Year and Enrolled Patient Population
- 8.3.3. Analysis by Trial Status
- 8.3.4. Analysis by Trial Registration Year and Trial Status
- 8.3.5. Analysis by Trial Phase
- 8.3.6. Analysis by Trial Phase and Enrolled Patient Population
- 8.3.7. Analysis by Target Patient Segment
- 8.3.8. Analysis by Type of Sponsor / Collaborator
- 8.3.9. Analysis by Study Design
- 8.3.10. Most Active Industry Players: Analysis by Number of Registered Trials
- 8.3.11. Most Active Non-Industry Players: Analysis by Number of Registered Trials
- 8.3.12. Analysis by Key Focus Areas (Word Cloud Representation)
- 8.3.13. Analysis of Clinical Trials by Geography
- 8.3.14. Analysis of Enrolled Patient Population by Geography
8.4. TCR-based Therapies: Clinical Trial Analysis
- 8.4.1. Analysis by Trial Registration Year
- 8.4.2. Analysis by Trial Registration Year and Enrolled Patient Population
- 8.4.3. Analysis by Trial Status
- 8.4.4. Analysis by Trial Registration Year and Trial Status
- 8.4.5. Analysis by Trial Phase
- 8.4.6. Analysis by Trial Phase and Enrolled Patient Population
- 8.4.7. Analysis by Target Patient Segment
- 8.4.8. Analysis by Type of Sponsor / Collaborator
- 8.4.9. Analysis by Study Design
- 8.4.10. Most Active Industry Players: Analysis by Number of Registered Trials
- 8.4.11. Most Active Non-Industry Players: Analysis by Number of Registered Trials
- 8.4.12. Analysis by Key Focus Areas (Word Cloud Representation)
- 8.4.13. Analysis of Clinical Trials by Geography
- 8.4.14. Analysis of Enrolled Patient Population by Geography
8.5. TIL-based Therapies: Clinical Trial Analysis
- 8.5.1. Analysis by Trial Registration Year
- 8.5.2. Analysis by Trial Registration Year and Enrolled Patient Population
- 8.5.3. Analysis by Trial Status
- 8.5.4. Analysis by Trial Registration Year and Trial Status
- 8.5.5. Analysis by Trial Phase
- 8.5.6. Analysis by Trial Phase and Enrolled Patient Population
- 8.5.7. Analysis by Target Patient Segment
- 8.5.8. Analysis by Type of Sponsor / Collaborator
- 8.5.9. Analysis by Study Design
- 8.5.10. Most Active Industry Players: Analysis by Number of Registered Trials
- 8.5.11. Most Active Non-Industry Players: Analysis by Number of Registered Trials
- 8.5.12. Analysis by Key Focus Areas (Word Cloud Representation)
- 8.5.13. Analysis of Clinical Trials by Geography
- 8.5.14. Analysis of Enrolled Patient Population by Geography

9. KEY OPINION LEADERS

9.1. Chapter Overview
9.2. Assumptions and Key Parameters
9.3. Methodology
9.4. CAR-T Cell Therapies: Key Opinion Leaders
- 9.4.1. Analysis by Type of Organization
- 9.4.2. Analysis by Affiliated Organization
- 9.4.3. Analysis by Qualification
- 9.4.4. Analysis by Geographical Location of KOLs
- 9.4.5. KOL Activeness versus KOL Strength
- 9.4.6. Most Prominent KOLs: Analysis by RA score
- 9.4.7. Most Prominent KOLs: Comparison of RA Score and Third-Party Score
9.5. TCR-based Therapies: Key Opinion Leaders
- 9.5.1. Analysis by Type of Organization
- 9.5.2. Analysis by Affiliated Organization
- 9.5.3. Analysis by Qualification
- 9.5.4. Analysis by Geographical Location of KOLs
- 9.5.5. KOL Activeness versus KOL Strength
- 9.5.6. Most Prominent KOLs: Analysis by RA score
- 9.5.7. Most Prominent KOLs: Comparison of RA Score and Third-Party Score
9.6. TIL-based Therapies: Key Opinion Leaders
- 9.6.1. Analysis by Type of Organization
- 9.6.2. Analysis by Affiliated Organization
- 9.6.3. Analysis by Qualification
- 9.6.4. Analysis by Geographical Location of KOLs
- 9.6.5. KOL Activeness versus KOL Strength
- 9.6.6. Most Prominent KOLs: Analysis by RA score
- 9.6.7. Most Prominent KOLs: Comparison of RA Score and Third-Party Score

10. CAR-T CELL THERAPY PROFILES

10.1. Chapter Overview
10.2. Kymriah / Tisagenlecleucel / CTL019 (Novartis)
- 10.2.1. Therapy Overview
- 10.2.2. Clinical Trial Information
- 10.2.3. Clinical Trial Endpoints
- 10.2.4. Clinical Trial Results
- 10.2.5. Estimated Sales Revenues
10.3. Yescarta / Axiscabtagene Ciloleucel / KTE-C19 (Gilead Sciences)
- 10.3.1. Therapy Overview
- 10.3.2. Clinical Trial Information
- 10.3.3. Clinical Trial Endpoints
- 10.3.4. Clinical Trial Results
- 10.3.5. Estimated Sales Revenues
10.4. Tecartus / Brexucabtagene Autoleucel (Gilead Sciences)
- 10.4.1. Therapy Overview
- 10.4.2. Clinical Trial Information
- 10.4.3. Clinical Trial Endpoints
- 10.4.4. Clinical Trial Results
- 10.4.5. Estimated Sales Revenues
10.5. Breyanzi / Lisocabtagene Maraleucel / JCAR017 (Bristol Myers Squibb)
- 10.5.1. Therapy Overview
- 10.5.2. Clinical Trial Information
- 10.5.3. Clinical Trial Endpoints
- 10.5.4. Clinical Trial Results
- 10.5.5. Estimated Sales Revenues
10.6. Abecma / BB2121 / Idecabtagene Vicleucel (Bristol Myers Squibb)
- 10.6.1. Therapy Overview
- 10.6.2. Clinical Trial Information
- 10.6.3. Clinical Trial Endpoints
- 10.6.4. Clinical Trial Results
- 10.6.5. Estimated Sales Revenues
10.7. Carvykti / Ciltacabtagene Autoleucel / LCAR-B38M CAR-T / JNJ-68284528 (Janssen)
- 10.7.1. Therapy Overview
- 10.7.2. Clinical Trial Information
- 10.7.3. Clinical Trial Endpoints
- 10.7.4. Clinical Trial Results
- 10.7.5. Estimated Sales Revenues
10.8. Carteyva / Relmacabtagene Autoleucel / JWCAR029 (JW Therapeutics)
- 10.8.1. Therapy Overview
- 10.8.2. Clinical Trial Information
- 10.8.3. Clinical Trial Endpoints
- 10.8.4. Clinical Trial Results
- 10.8.5. Estimated Sales Revenues
10.9. TBI-1501 / CD19 CAR-T Cell Therapy (Takara Bio)
- 10.9.1. Therapy Overview
- 10.9.2. Clinical Trial Information
- 10.9.3. Clinical Trial Endpoints
- 10.9.4. Estimated Sales Revenues
10.10. AUTO1 / Obecabtagene Autoleucel / obe-cel (Autolus)
- 10.10.1. Therapy Overview
- 10.10.2. Clinical Trial Information
- 10.10.3. Clinical Trial Endpoints
- 10.10.4. Clinical Trial Results
- 10.10.5. Estimated Sales Revenues
10.11. AUTO3 / CD19/22 CAR-T (Autolus)
- 10.11.1. Therapy Overview
- 10.11.2. Clinical Trial Information
- 10.11.3. Clinical Trial Endpoints
- 10.11.4. Clinical Trial Results
- 10.11.5. Estimated Sales Revenues

11. TCR-BASED THERAPY PROFILES

11.1. Chapter Overview
11.2. Kimmtrak / IMCgp100 / Tebentafusp (Immunocore)
- 11.2.1. Therapy Overview
- 11.2.2. Clinical Trial Information
- 11.2.3. Clinical Trial Endpoints
- 11.2.4. Clinical Trial Results
- 11.2.5. Estimated Sales Revenues
11.3. GSK3377794 / NY-ESO-1C259 T-Cells / Letetresgene Autoleucel (GlaxoSmithKline)
- 11.3.1. Therapy Overview
- 11.3.2. Clinical Trial Information
- 11.3.3. Clinical Trial Endpoints
- 11.3.4. Clinical Trial Results
- 11.3.5. Estimated Sales Revenues
11.4. ADP-A2M4 / Afamitresgene Autoleucel / Afami-cel (Adaptimmune Therapeutics)
- 11.4.1. Therapy Overview
- 11.4.2. Clinical Trial Information
- 11.4.3. Clinical Trial Endpoints
- 11.4.4. Clinical Trial Results
- 11.4.5. Estimated Sales Revenues
11.5. JTCR016 (Juno Therapeutics)
- 11.5.1. Therapy Overview
- 11.5.2. Clinical Trial Information
- 11.5.3. Clinical Trial Endpoints
- 11.5.4. Estimated Sales Revenues
11.6. TBI-1301 (Takara Bio)
- 11.6.1. Therapy Overview
- 11.6.2. Clinical Trial Information
- 11.6.3. Clinical Trial Endpoints
- 11.6.4. Clinical Trial Results
- 11.6.5. Estimated Sales Revenues
11.7. MDG1011 (Medigene)
- 11.7.1. Therapy Overview
- 11.7.2. Clinical Trial Information
- 11.7.3. Clinical Trial Endpoints
- 11.7.4. Clinical Trial Results
- 11.7.5. Estimated Sales Revenues

12. TIL-BASED THERAPY PROFILES

12.1. Chapter Overview
12.2. LN-144 / Lifileucel (Iovance Biotherapeutics)
- 12.2.1. Therapy Overview
- 12.2.2. Clinical Trial Information
- 12.2.3. Clinical Trial Endpoints
- 12.2.4. Clinical Trial Results
- 12.2.5. Estimated Sales Revenues
12.3. LN-145 (Iovance Biotherapeutics)
- 12.3.1. Therapy Overview
- 12.3.2. Clinical Trial Information
- 12.3.3. Clinical Trial Endpoints
- 12.3.4. Clinical Trial Results
- 12.3.5. Estimated Sales Revenues
12.4. ITIL-168 (Instil Bio)
- 12.4.1. Therapy Overview
- 12.4.2. Clinical Trial Information
- 12.4.3. Clinical Trial Endpoints
- 12.4.4. Clinical Trial Results
- 12.4.5. Estimated Sales Revenues
12.5. LTX-315 (Lytix Biopharma)
- 12.5.1. Therapy Overview
- 12.5.2. Clinical Trial Information
- 12.5.3. Clinical Trial Endpoints
- 12.5.4. Clinical Trial Results
- 12.5.5. Estimated Sales Revenues

13. EMERGING TECHNOLOGIES

13.1. Chapter Overview
13.2. Genome Editing Technologies
- 13.2.1. Technology Overview
- 13.2.2. Applications of Genome Editing Technologies
- 13.2.3. Emerging Technology Platforms for T-Cell Therapies
  - 13.2.3.1. CRISPR / CAS9 System
    - 13.2.3.1.1. Key Components
    - 13.2.3.1.2. Mechanism of Action
    - 13.2.3.1.3. Targeting Efficiency and Challenges
    - 13.2.3.1.4. Next-Gen CRISPR Technology
    - 13.2.3.1.5. Technology Providers
      - 13.2.3.1.5.1. Intellia Therapeutics
      - 13.2.3.1.5.2. Editas Medicine
      - 13.2.3.1.5.3. CRISPR Therapeutics
      - 13.2.3.1.5.4. Beam Therapeutics
      - 13.2.3.1.5.5. Gracell Technologies
      - 13.2.3.1.5.6. Caribou Biosciences
      - 13.2.3.1.5.7. Nanjing Bioheng Biotech
      - 13.2.3.1.5.8. Intima Biosciences
      - 13.2.3.1.5.9. KSQ Therapeutics
      - 13.2.3.1.5.10. Refuge Biotechnologies
  - 13.2.3.2. TALENS
    - 13.2.3.2.1. Key Components and Function
    - 13.2.3.2.2. Mechanism of Action
    - 13.2.3.2.3. Advantages and Challenges
    - 13.2.3.2.4. Technology Providers
      - 13.2.3.2.4.1. Cellectis
      - 13.2.3.2.4.2. Editas Medicine
  - 13.2.3.3. MegaTAL
    - 13.2.3.3.1. Mechanism of Action
    - 13.2.3.3.2. Technology Providers
      - 13.2.3.3.2.1. bluebird bio
      - 13.2.3.3.2.2. Precision Biosciences
  - 13.2.3.4. Zinc Finger Nuclease
    - 13.2.3.4.1. Mechanism of Action
    - 13.2.3.4.2. Technology Providers
      - 13.2.3.4.2.1. Sangamo Therapeutics
- 13.2.4. Competitive Analysis: Gene Editing Platforms
13.3. Designing T-Cell Therapies with Improved Characteristics
- 13.3.1. Technologies for Targeting Multiple Cancers
  - 13.3.1.1. Antibody Coupled T-Cell Receptor
    - 13.3.1.1.1. Cogent Biosciences
  - 13.3.1.2. NKR-T Platform
    - 13.3.1.2.1. Celyad
    - 13.3.1.2.2. Glycostem
    - 13.3.1.2.3. CatamaranBio
- 13.3.2. Technologies for Improved Safety
  - 13.3.2.1. Armored CAR and EGFRt Technology
    - 13.3.2.1.1. Juno Therapeutics
  - 13.3.2.2. Rheoswitch Therapeutic System
    - 13.3.2.2.1. Intrexon
    - 13.3.2.2.2. Precigen
  - 13.3.2.3. Inducible Caspase 9 Safety Switch
    - 13.3.2.3.1. Bellicum Pharmaceuticals
      - 13.3.2.3.1.1. CaspaCIDe Technology
      - 13.3.2.3.1.2. CIDeCAR Technology
      - 13.3.2.3.1.3. GoCAR-T Technology
  - 13.3.2.4. On-OFF Switch, Multiple Companies
    - 13.3.2.4.1. Inhibitory CAR (iCAR) (Juno Therapeutics)
    - 13.3.2.4.2. On-OFF Switch (Theravectys)
  - 13.3.2.5. Other Technologies to Improve CAR-T Safety
- 13.3.3. Allogeneic Technologies
  - 13.3.3.1. CIK CAR-T Cells (Formula Pharmaceuticals)
  - 13.3.3.2. Allogeneic Platform (CELYAD)
  - 13.3.3.3. Allogeneic Platform (Cellectis)
  - 13.3.3.4. AlloCAR T (Allogene Therapeutics)
13.4. Future Perspectives

14. PARTNERSHIPS AND COLLABORATIONS

14.1. Chapter Overview
14.2. Partnership Models
14.3. T-Cell Immunotherapies Market: Partnerships and Collaborations
- 14.3.1. Analysis by Year of Partnership
- 14.3.2. Analysis by Type of Partnership
- 14.3.3. Analysis by Type of Product
- 14.3.4. Analysis by Year of Partnership and Type of Product
- 14.3.5. Analysis by Type of Partnership and Type of Product
- 14.3.6. Analysis by Type of Partner
- 14.3.7. Analysis by Type of Product and Type of Partner
- 14.3.8. Most Popular Products: Analysis by Number of Partnerships
- 14.3.9. Most Active Industry Players: Analysis by Number of Partnerships
- 14.3.10. Most Active Non-Industry Players: Analysis by Number of Partnerships
- 14.3.11. Analysis by Geography
  - 14.3.11.1. Intercontinental and Intracontinental Agreements
  - 14.3.11.2. International and Local Deals

15. FUNDING AND INVESTMENT ANALYSIS

15.1. Chapter Overview
15.2. Type of Funding
15.3. T-Cell Immunotherapy Market: Funding and Investment Analysis
- 15.3.1. Analysis of Instances by Year
- 15.3.2. Analysis of Amount Invested by Year
- 15.3.3. Analysis by Type of Funding
- 15.3.4. Analysis of Amount Invested across Different Types of Therapies
- 15.3.5. Analysis by Type of Investor
- 15.3.6. Most Active Players: Analysis by Number of Instances
- 15.3.7. Most Active Investors: Analysis by Amount Invested
- 15.3.8. Analysis of Amount Invested by Geography
- 15.3.9. Most Active Investors: Analysis by Number of Funding Instances

16. PATENT ANALYSIS

16.1. Chapter Overview
16.2. Scope and Methodology
16.3. Patent Analysis: Distribution by Type of Patent
16.4. CAR-T Cell Therapies: Patent Analysis
- 16.4.1. Analysis by Patent Publication Year
- 16.4.2. Analysis by Patent Application Year
- 16.4.3. Analysis by Geography
- 16.4.4. Analysis by Type of Player
- 16.4.5. Analysis by CPC Symbols
- 16.4.6. Analysis by Key Focus Area
- 16.4.7. Leading Players: Analysis by Number of Patents
- 16.4.8. Car-T Cell Therapies: Patent Benchmarking
- 16.4.9. Analysis By Patent Characteristics
- 16.4.10. Car-T Cell Therapies: Patent Valuation
16.5. TCR- based Therapies
- 16.5.1. Analysis by Patent Publication Year
- 16.5.2. Analysis By Patent Application Year
- 16.5.3. Analysis by Geography
- 16.5.4. Analysis by Type of Player
- 16.5.5. Analysis by CPC Symbols
- 16.5.6. Analysis by Key Focus Area
- 16.5.7. Leading Player: Analysis by Number of Patents
- 16.5.8. TCR-based Therapies: Patent Benchmarking
- 16.5.9. Analysis By Patent Characteristics
- 16.5.10. TCR-based Cell Therapies: Patent Valuation
16.6. TIL- based Therapies
- 16.6.1. Analysis by Patent Publication Year
- 16.6.2. Analysis By Patent Application Year
- 16.6.3. Analysis by Geography
- 16.6.4. Analysis by Type of Player
- 16.6.5. Analysis by CPC Symbols
- 16.6.6. Analysis by Key Focus Area
- 16.6.7. Leading Player: Analysis by Number of Patents
- 16.6.8. TIL-based Therapies: Patent Benchmarking
- 16.6.9. Analysis By Patent Characteristics
- 16.6.10. TIL-based Therapies: Patent Valuation

17. OTHER T-CELL IMMUNOTHERAPIES

17.1. Chapter Overview
17.2. Other T-Cell Immunotherapies
- 17.2.1. Fucosylated T-Cell Therapies
- 17.2.2. Gamma Delta T-Cell Therapies
- 17.2.3. PD-1 Knockout Engineered T-Cell Therapies
- 17.2.4. TAC T-Cell Therapies
- 17.2.5. T-Cell Vaccines
- 17.2.6. Treg Cell Therapies
- 17.2.7. Virus-Driven T-Cell Therapies
17.3. Other T-Cell Immunotherapies: Market Overview
- 17.3.1. Analysis by Type of T-Cell
- 17.3.2. Analysis by Source of T-Cell
- 17.3.3. Analysis by Phase of Development
- 17.3.4. Analysis by Therapeutic Area
17.4. Key Considerations for Developing T-Cell Immunotherapies
17.5. Concluding Remarks

18. CASE STUDY: CELL THERAPY MANUFACTURING

18.1. Chapter Overview
18.2. Overview of Cell Therapy Manufacturing
18.3. Cell Therapy Manufacturing Models
- 18.3.1. Centralized Manufacturing Model
- 18.3.2. Decentralized Manufacturing Model
18.4. Scalability of Cell Therapy Manufacturing Processes
- 18.4.1. Scale-Up
- 18.4.2. Scale-Out
18.5. Types of Cell Therapy Manufacturers
18.6. Key Challenges Related to Manufacturing of Cell Therapies
18.7. Important Factors for Cell Therapy Manufacturing
- 18.7.1. Characterization
- 18.7.2. Cost of Goods
18.8. Automation of Cell Therapy Manufacturing Process
18.9. Cell Therapy Manufacturing Supply Chain
18.10. Comparison of Player Having In-House Capabilities and Contract Manufacturers
18.11. Regulatory Landscape
18.12. Future Perspectives

19. COST PRICE ANALYSIS

19.1. Chapter Overview
19.2. Factors Contributing to the High Price of Cell / Gene Therapies
19.3. Pricing Models for T-Cell Immunotherapies
- 19.3.1. Based on Associated Costs
- 19.3.2. Based on Availability of Competing Products
- 19.3.3. Based on Patient Segment
- 19.3.4. Based on Opinions of Industry Experts
19.4. Reimbursement related Considerations for T-Cell Immunotherapies
- 19.4.1. Case Study: The National Institute for Health and Care Excellence (NICE) Appraisal of CAR-T therapies

20. MARKET FORECAST AND OPPORTUNITY ANALYSIS

20.1. Chapter Overview
20.2. Scope and Limitations
20.3. Key Assumptions And Forecast Methodology
20.4. Overall T-Cell Immunotherapy Market, 2022-2035
- 20.4.1. T-Cell Immunotherapy Market: Analysis by Type of Therapy
- 20.4.2. T-Cell Immunotherapy Market: Analysis by Target Indication
- 20.4.3. T-Cell Immunotherapy Market: Analysis by Target Antigen
- 20.4.4. T-Cell Immunotherapy Market: Analysis by Key Players
- 20.4.5. T-Cell Immunotherapy Market: Analysis by Geography
20.5. T-Cell Immunotherapy Market: Value Creation Analysis
20.6. Overall CAR-T Cell Therapies Market, 2022-2035
- 20.6.1. CAR-T Cell Therapies Market: Analysis by Target Indication
- 20.6.2. CAR-T Cell Therapies Market: Analysis by Target Antigen
- 20.6.3. CAR-T Cell Therapies Market: Analysis by Key Players
- 20.6.4. CAR-T Cell Therapies Market: Analysis by Geography
- 20.6.5. Product Wise Sales Forecast
  - 20.6.5.1. Kymriah / Tisagenlecleucel / CTL019 (Novartis)
    - 20.6.5.1.1. Sales Forecast (USD Million)
    - 20.6.5.1.2. Net Present Value
    - 20.6.5.1.3. Value Creation Analysis
  - 20.6.5.2. Yescarta / Axiscabtagene Ciloleucel / KTE-C19 (Gilead Sciences)
    - 20.6.5.2.1. Sales Forecast (USD Million)
    - 20.6.5.2.2. Net Present Value (USD Million)
    - 20.6.5.2.3. Value Creation Analysis
  - 20.6.5.3. Tecartus / Brexucabtagene Autoleucel (Gilead Sciences)
    - 20.6.5.3.1. Sales Forecast (USD Million)
    - 20.6.5.3.2. Net Present Value (USD Million)
    - 20.6.5.3.3. Value Creation Analysis
  - 20.6.5.4. Abecma / BB2121 / Idecabtagene Vicleucel (Bristol Myers Squibb)
    - 20.6.5.4.1. Sales Forecast (USD Million)
    - 20.6.5.4.2. Net Present Value (USD Million)
    - 20.6.5.4.3. Value Creation Analysis
  - 20.6.5.5. Carvykti / Ciltacabtagene Autoleucel / LCAR-B38M CAR-T / JNJ-68284528 (Janssen)
    - 20.6.5.5.1. Sales Forecast (USD Million)
    - 20.6.5.5.2. Net Present Value (USD Million)
    - 20.6.5.5.3. Value Creation Analysis
  - 20.6.5.6. Breyanzi / Lisocabtagene Maraleucel / JCAR017 (Bristol Myers Squibb)
    - 20.6.5.6.1. Sales Forecast (USD Million)
    - 20.6.5.6.2. Net Present Value (USD Million)
    - 20.6.5.6.3. Value Creation Analysis
  - 20.6.5.7. Carteyva / Relmacabtagene Autoleucel / JWCAR029 (JW Therapeutics)
    - 20.6.5.7.1. Sales Forecast (USD Million)
    - 20.6.5.7.2. Net Present Value (USD Million)
    - 20.6.5.7.3. Value Creation Analysis
  - 20.6.5.8. BCMA CAR-T Cells (Shanghai Unicar-Therapy Bio-medicine Technology)
    - 20.6.5.8.1. Sales Forecast (USD Million)
    - 20.6.5.8.2. Net Present Value (USD Million)
    - 20.6.5.8.3. Value Creation Analysis
  - 20.6.5.9. CD19 CAR-T (Wuhan Si'an Medical Technology)
    - 20.6.5.9.1. Sales Forecast (USD Million)
    - 20.6.5.9.2. Net Present Value (USD Million)
    - 20.6.5.9.3. Value Creation Analysis
  - 20.6.5.10. Descartes-11 (Cartesian Therapeutics)
    - 20.6.5.10.1. Sales Forecast (USD Million)
    - 20.6.5.10.2. Net Present Value (USD Million)
    - 20.6.5.10.3. Value Creation Analysis
  - 20.6.5.11. Descartes-08 (Cartesian Therapeutics)
    - 20.6.5.11.1. Sales Forecast (USD Million)
    - 20.6.5.11.2. Net Present Value (USD Million)
    - 20.6.5.11.3. Value Creation Analysis
  - 20.6.5.12. Zamtocabtagene Autoleucel / MB-CART2019.1 (Miltenyi Biomedicine)
    - 20.6.5.12.1. Sales Forecast (USD Million)
    - 20.6.5.12.2. Net Present Value (USD Million)
    - 20.6.5.12.3. Value Creation Analysis
  - 20.6.5.13. CNCT19 / HY001 (Juventas Cell Therapy)
    - 20.6.5.13.1. Sales Forecast (USD Million)
    - 20.6.5.13.2. Net Present Value (USD Million)
    - 20.6.5.13.3. Value Creation Analysis
  - 20.6.5.14. CD30.CAR-T / TT11 (Tessa Therapeutics)
    - 20.6.5.14.1. Sales Forecast (USD Million)
    - 20.6.5.14.2. Net Present Value (USD Million)
    - 20.6.5.14.3. Value Creation Analysis
  - 20.6.5.15. TAK-007 (Takeda)
    - 20.6.5.15.1. Sales Forecast (USD Million)
    - 20.6.5.15.2. Net Present Value (USD Million)
    - 20.6.5.15.3. Value Creation Analysis
  - 20.6.5.16. AUTO1 (Autolus)
    - 20.6.5.16.1. Sales Forecast (USD Million)
    - 20.6.5.16.2. Net Present Value (USD Million)
    - 20.6.5.16.3. Value Creation Analysis
  - 20.6.5.17. AUTO3 (Autolus)
    - 20.6.5.17.1. Sales Forecast (USD Million)
    - 20.6.5.17.2. Net Present Value (USD Million)
    - 20.6.5.17.3. Value Creation Analysis
  - 20.6.5.18. CD19-CAR-T (Bioray Laboratories)
    - 20.6.5.18.1. Sales Forecast (USD Million)
    - 20.6.5.18.2. Net Present Value (USD Million)
    - 20.6.5.18.3. Value Creation Analysis
  - 20.6.5.19. Humanized CD19-CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology)
    - 20.6.5.19.1. Sales Forecast (USD Million)
    - 20.6.5.19.2. Net Present Value (USD Million)
    - 20.6.5.19.3. Value Creation Analysis
  - 20.6.5.20. IM19 CAR-T (Beijing Immunochina Medical Science & Technology)
    - 20.6.5.20.1. Sales Forecast (USD Million)
    - 20.6.5.20.2. Net Present Value (USD Million)
    - 20.6.5.20.3. Value Creation Analysis
  - 20.6.5.21. CCT301 CAR-T (Shanghai PerHum Therapeutics)
    - 20.6.5.21.1. Sales Forecast (USD Million)
    - 20.6.5.21.2. Net Present Value (USD Million)
    - 20.6.5.21.3. Value Creation Analysis
  - 20.6.5.22. BinD19 (Shenzhen BinDeBio)
    - 20.6.5.22.1. Sales Forecast (USD Million)
    - 20.6.5.22.2. Net Present Value (USD Million)
    - 20.6.5.22.3. Value Creation Analysis
  - 20.6.5.23. CARCIK-CD19 (CoImmune)
    - 20.6.5.23.1. Sales Forecast (USD Million)
    - 20.6.5.23.2. Net Present Value (USD Million)
    - 20.6.5.23.3. Value Creation Analysis
  - 20.6.5.24. PBCAR269A (Precision BioSciences / Servier)
    - 20.6.5.24.1. Sales Forecast (USD Million)
    - 20.6.5.24.2. Net Present Value (USD Million)
    - 20.6.5.24.3. Value Creation Analysis
  - 20.6.5.25. CD123 CAR-T cells (Chongqing Precision Biotechnology)
    - 20.6.5.25.1. Sales Forecast (USD Million)
    - 20.6.5.25.2. Net Present Value (USD Million)
    - 20.6.5.25.3. Value Creation Analysis
  - 20.6.5.26. BCMA CAR-T (Chongqing Precision Biotechnology)
    - 20.6.5.26.1. Sales Forecast (USD Million)
    - 20.6.5.26.2. Net Present Value (USD Million)
    - 20.6.5.26.3. Value Creation Analysis
  - 20.6.5.27. CD19/CD22-CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology)
    - 20.6.5.27.1. Sales Forecast (USD Million)
    - 20.6.5.27.2. Net Present Value (USD Million)
    - 20.6.5.27.3. Value Creation Analysis
  - 20.6.5.28. GC012F / Dual CAR-BCMA-19 (Gracell Biotechnology)
    - 20.6.5.28.1. Sales Forecast (USD Million)
    - 20.6.5.28.2. Net Present Value (USD Million)
    - 20.6.5.28.3. Value Creation Analysis
  - 20.6.5.29. iC9-CAR19 T cells (Bellicum Pharmaceuticals)
    - 20.6.5.29.1. Sales Forecast (USD Million)
    - 20.6.5.29.2. Net Present Value (USD Million)
    - 20.6.5.29.3. Value Creation Analysis
  - 20.6.5.30. ALLO-501A / ALLO-501 (Allogene Therapeutics)
    - 20.6.5.30.1. Sales Forecast (USD Million)
    - 20.6.5.30.2. Net Present Value (USD Million)
    - 20.6.5.30.3. Value Creation Analysis
  - 20.6.5.31. CD19/CD20-CAR-T (Yake Biotechnology)
    - 20.6.5.31.1. Sales Forecast (USD Million)
    - 20.6.5.31.2. Net Present Value (USD Million)
    - 20.6.5.31.3. Value Creation Analysis
  - 20.6.5.32. CD7 CAR-T (PersonGen BioTherapeutics)
    - 20.6.5.32.1. Sales Forecast (USD Million)
    - 20.6.5.32.2. Net Present Value (USD Million)
    - 20.6.5.32.3. Value Creation Analysis
  - 20.6.5.33. Anti-FLT3 CAR-T / TAA05 (PersonGen BioTherapeutics)
    - 20.6.5.33.1. Sales Forecast (USD Million)
    - 20.6.5.33.2. Net Present Value (USD Million)
    - 20.6.5.33.3. Value Creation Analysis
  - 20.6.5.34. CT053 (CARsgen Therapeutics)
    - 20.6.5.34.1. Sales Forecast (USD Million)
    - 20.6.5.34.2. Net Present Value (USD Million)
    - 20.6.5.34.3. Value Creation Analysis
  - 20.6.5.35. Anti-ALPP CAR-T Cells (TCRCure Biopharma)
    - 20.6.5.35.1. Sales Forecast (USD Million)
    - 20.6.5.35.2. Net Present Value (USD Million)
    - 20.6.5.35.3. Value Creation Analysis
  - 20.6.5.36. BCMA targeted prime CAR-T cells (Chongqing Precision Biotechnology)
    - 20.6.5.36.1. Sales Forecast (USD Million)
    - 20.6.5.36.2. Net Present Value (USD Million)
    - 20.6.5.36.3. Value Creation Analysis
  - 20.6.5.37. ALLO-605 (Allogene Therapeutics)
    - 20.6.5.37.1. Sales Forecast (USD Million)
    - 20.6.5.37.2. Net Present Value (USD Million)
    - 20.6.5.37.3. Value Creation Analysis
  - 20.6.5.38. WU CART 007 (Wugen)
    - 20.6.5.38.1. Sales Forecast (USD Million)
    - 20.6.5.38.2. Net Present Value (USD Million)
    - 20.6.5.38.3. Value Creation Analysis
  - 20.6.5.39. CT103A (Nanjing IASO Biotherapeutics)
    - 20.6.5.39.1. Sales Forecast (USD Million)
    - 20.6.5.39.2. Net Present Value (USD Million)
    - 20.6.5.39.3. Value Creation Analysis
20.7. Overall TCR-based Therapies Market
- 20.7.1. TCR-Based Therapies Market: Analysis by Target Indication
- 20.7.2. TCR-Based Therapies Market: Analysis by Target Antigen
- 20.7.3. TCR-Based Therapies Market: Analysis by Key Players
- 20.7.4. TCR-Based Therapies Market: Analysis by Geography
- 20.7.5. Product Wise Sales Forecast
  - 20.7.5.1 Kimmtrak (IMCgp100 / Tebentafusp) (Immunocore)
    - 20.7.5.1.1. Sales Forecast (USD Million)
    - 20.7.5.1.2. Net Present Value (USD Million)
    - 20.7.5.1.3. Value Creation Analysis
  - 20.7.5.2. GSK3377794 (GlaxoSmithKline)
    - 20.7.5.2.1. Sales Forecast (USD Million)
    - 20.7.5.2.2. Net Present Value (USD Million)
    - 20.7.5.2.3. Value Creation Analysis
  - 20.7.5.3. YT-E001 (China Immunotech)
    - 20.7.5.3.1. Sales Forecast (USD Million)
    - 20.7.5.3.2. Net Present Value (USD Million)
    - 20.7.5.3.3. Value Creation Analysis
  - 20.7.5.4. ADP-A2M4 / Afamitresgene Autoleucel / Afami-cel (Adaptimmune Therapeutics)
    - 20.7.5.4.1. Sales Forecast (USD Million)
    - 20.7.5.4.2. Net Present Value (USD Million)
    - 20.7.5.4.3. Value Creation Analysis
  - 20.7.5.5. EBV-specific TCR-T cell with anti-PD1 auto-secreted element (TCRCure Biopharma)
    - 20.7.5.5.1. Sales Forecast (USD Million)
    - 20.7.5.5.2. Net Present Value (USD Million)
    - 20.7.5.5.3. Value Creation Analysis
  - 20.7.5.6. NTLA-5001 (Intellia Therapeutics)
    - 20.7.5.6.1. Sales Forecast (USD Million)
    - 20.7.5.6.2. Net Present Value (USD Million)
    - 20.7.5.6.3. Value Creation Analysis
  - 20.7.5.7. TBI-1301 (Takara Bio)
    - 20.7.5.7.1. Sales Forecast (USD Million)
    - 20.7.5.7.2. Net Present Value (USD Million)
    - 20.7.5.7.3. Value Creation Analysis
  - 20.7.5.8. LMBP2-specific TCR-T (Xinqiao Hospital of Chongqing / TCR CURE Biopharma Technology)
    - 20.7.5.8.1. Sales Forecast (USD Million)
    - 20.7.5.8.2. Net Present Value (USD Million)
    - 20.7.5.8.3. Value Creation Analysis
  - 20.7.5.9. FH-MCVA2TCR (TCRCure Biopharma)
    - 20.7.5.9.1. Sales Forecast (USD Million)
    - 20.7.5.9.2. Net Present Value (USD Million)
    - 20.7.5.9.3. Value Creation Analysis
20.8. Overall TIL-Based Therapies Market
- 20.8.1. TIL-Based Therapies Market: Analysis by Target Indication
- 20.8.2. TIL-Based Therapies Market: Analysis by Key Players
- 20.8.3. TIL-Based Therapies Market: Analysis by Geography
  - 20.8.3.1. Lifileucel / LN-144 (Iovance Biotherapeutics)
    - 20.8.3.1.1. Sales Forecast (USD Million)
    - 20.8.3.1.2. Net Present Value (USD Million)
    - 20.8.3.1.3. Value Creation Analysis
  - 20.8.3.2. LN-145 (Iovance Biotherapeutics)
    - 20.8.3.2.1. Sales Forecast (USD Million)
    - 20.8.3.2.2. Net Present Value (USD Million)
    - 20.8.3.2.3. Value Creation Analysis
  - 20.8.3.3. LTX-315 and TILs (Lytix Biopharma)
    - 20.8.3.3.1. Sales Forecast (USD Million)
    - 20.8.3.3.2. Net Present Value (USD Million)
    - 20.8.3.3.3. Value Creation Analysis
  - 20.8.3.4. TILs (Prometheus Laboratories)
    - 20.8.3.4.1. Sales Forecast (USD Million)
    - 20.8.3.4.2. Net Present Value (USD Million)
    - 20.8.3.4.3. Value Creation Analysis
  - 20.8.3.5. Donor Lymphocyte Infusion (Incyte)
    - 20.8.3.5.1. Sales Forecast (USD Million)
    - 20.8.3.5.2. Net Present Value (USD Million)
    - 20.8.3.5.3. Value Creation Analysis
  - 20.8.3.6. ITIL-168 (Instil Bio)
    - 20.8.3.6.1. Sales Forecast (USD Million)
    - 20.8.3.6.2. Net Present Value (USD Million)
    - 20.8.3.6.3. Value Creation Analysis
  - 20.8.3.7. IOV-2001 (Iovance Biotherapeutics)
    - 20.8.3.7.1. Sales Forecast (USD Million)
    - 20.8.3.7.2. Net Present Value (USD Million)
    - 20.8.3.7.3. Value Creation Analysis
  - 20.8.3.8. TILs (CAR-T (Shanghai) Cell Biotechnology)
    - 20.8.3.8.1. Sales Forecast (USD Million)
    - 20.8.3.8.2. Net Present Value (USD Million)
    - 20.8.3.8.3. Value Creation Analysis
  - 20.8.3.9. TILs (Bristol-Myers Squibb)
    - 20.8.3.9.1. Sales Forecast (USD Million)
    - 20.8.3.9.2. Net Present Value (USD Million)
    - 20.8.3.9.3. Value Creation Analysis

21. PROMOTIONAL ANALYSIS

21.1. Chapter Overview
21.2. Channels Used for Promotional Campaigns
21.3. Summary of Product Website Analysis
21.4. Summary of Patient Support Services and Informative Downloads
21.5. Kymriah: Promotional Analysis
- 21.5.1. Drug Overview
- 21.5.2. Product Website Analysis
  - 21.5.2.3. Informative Downloads
- 21.5.3. Patient Support Services
21.6. Yescarta: Promotional Analysis
- 21.6.1. Drug Overview
- 21.6.2. Product Website Analysis
  - 21.6.2.3. Informative Downloads
- 21.6.3. Patient Support Services
21.7. Tecartus: Promotional Analysis
- 21.7.1. Drug Overview
- 21.7.2. Product Website Analysis
- 21.7.3. Patient Support Services
21.8. Breyanzi: Promotional Analysis
- 21.8.1. Drug Overview
- 21.8.2. Product Website Analysis
- 21.8.3. Patient Support Services
21.9. Abecma: Promotional Analysis
- 21.9.1. Drug Overview
- 21.9.2. Product Website Analysis
- 21.9.3. Patient Support Services
21.10. Carvykti: Promotional Analysis
- 21.10.1. Drug Overview
- 21.10.2. Product Website Analysis
- 21.10.3. Patient Support Services
21.11. Kimmtrak: Promotional Analysis
- 21.11.1. Drug Overview
- 21.11.2. Product Website Analysis
- 21.11.3. Patient Support Services

22. COMPANY PROFILES

22.1. Chapter Overview
22.2. Adaptimmune Therapeutics
22.3. Alaunos Therapeutics
22.4. Autolus
22.5. bluebird Bio
22.6. Bristol Myers Squibb
22.7. Carsgen Therapeutics
22.8. Cellectis
22.9. Cellular Biomedicine Group
22.10. Gilead Sciences
22.11. GlaxoSmithKline
22.12. Immatics
22.13. Immunocore
22.14. Innovative Cellular Therapeutics
22.15. Iovance Biotherapeutics
22.16. Kuur Therapeutics
22.17. Lion TCR
22.18. Noile-Immune Biotech
22.19. Novartis
22.20. Shanghai GeneChem
22.21. Sinobioway Cell Therapy
22.22. Takara Bio
22.23. Wellington Zhaotai Therapies
22.24. Zelluna immunotherapy

23. CONCLUDING REMARKS

24. EXECUTIVE INSIGHTS

24.1. Chapter Overview
24.2. Cell Therapies
- 24.2.1. Interview Transcript: Tim Oldham, Former Chief Executive Officer
24.3. Glycostem Therapeutics
- 24.3.1. Interview Transcript: Troels Jordansen, Chief Executive Officer
24.4. Gracell Biotechnologies
- 24.4.1. Interview Transcript: Wei (William) Cao, Chief Executive Officer
24.5. Lion TCR
- 24.5.1. Interview Transcript: Victor Lietao Li, Co-Founder and Chief Executive Officer
24.6. TxCell
- 24.6.1. Interview Transcript: Miguel Forte, Chief Executive Officer
24.7. Kite Pharma
- 24.7.1. Interview Transcript: Adrian Bot, Vice President, Scientific Affairs
24.8. Celyad
- 24.8.1. Interview Transcript: Vincent Brichard, Vice President, Immuno-Oncology
24.9. Iovance Biotherapeutics
- 24.9.1. Interview Transcript: Peter Ho, Former Director, Process Development
24.10. Waisman Biomanufacturing
- 24.10.1. Interview Transcript: Brian Dattilo, Director, Business Development
24.11. Theravectys
- 24.11.1. Interview Transcript: Aino Kalervo, Former Competitive Intelligence Manager, Strategy & Business Development
24.12. Changhai Hospital
- 24.12.1. Interview Transcript: Xian-Bao Zhan, Professor of Medicine and Director, Department of Oncology
24.13. University of Colorado
- 24.13.1. Interview Transcript: Enkhtsetseg Purev, Assistant Professor of Medicine

25. APPENDIX 1: TABULATED DATA

26. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS